Pharming N : H1 2022 Financial Results Presentation

Pharming Group N.V.

H1 2022 Financial Results

Analyst Call

August 4, 2022

NASDAQ: PHAR | EURONEXT Amsterdam: PHARM

Forward looking statements

This presentation may contain forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our clinical results and other future conditions. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial or business performance, conditions, plans, prospects, trends or strategies, objectives of management and other financial and business matters; our current and prospective product candidates, planned clinical trials and preclinical studies, projected research and development costs, current and prospective collaborations; and the estimated size of the market for our product candidates, the timing and success of our development and commercialization of our product candidates and the market acceptance thereof, are forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. While we may elect to update these forward-looking statements at some point in the future, we assume no obligation to update or revise any forward-looking statements except to the extent required by applicable law. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

This presentation is not a prospectus, and it does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

2

SPEAKERS

Sijmen de Vries	Anurag Relan	Jeroen Wakkerman
Chief Executive Officer	Chief Medical Officer	Chief Financial Officer

CEO

Sijmen de Vries

Chief Executive Officer

Strategic and operational highlights

Pharming's strategic objectives

Building a sustainable business by focusing

on RUCONEST® sales

Focus on Market approval, launch and commercialization of leniolisib in

key markets of US, UK and EEA

Ongoing pipeline development and management of rare disease assets

5